Phaseline

Companies › LigaChem Biosciences

LigaChem Biosciences: clinical trials, targets and expected readouts

4 active drug programs in 10 registered trials: 6 Phase 1, 4 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Anti-PD-1 monoclonal antibody
PD-1 inhibitor
PDCD1Phase 1Advanced Solid Tumors; Relapsed/Refractory Peripheral T-cell Lymphoma; Renal Cell Carcinoma; Solid Tumors …Jan 2027
LCB84
TROP2-directed antibody-drug conjugate with monomethyl auristatin E (MMAE)
TROP2Phase 1Advanced Solid TumorsJan 2027
LNCB74
antibody drug conjugate
–Phase 1Ovarian CancerDec 2027
LCB02A
anti-CLDN18.2 antibody-drug conjugate with topoisomerase I inhibitor payload
CLDN18Phase 1Advanced Solid TumorsFeb 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05182957Anti-PD-1 monoclonal antibodyPhase 2Relapsed/Refractory Peripheral T-cell LymphomaOncologyDec 2023
NCT06255223Anti-PD-1 monoclonal antibodyPhase 2Renal Cell CarcinomaOncologySep 2026
NCT05522582Anti-PD-1 monoclonal antibodyPhase 2Solid TumorsOncologyDec 2026
NCT05941507LCB84Phase 1Advanced Solid TumorsOncologyJan 2027
NCT05941507Anti-PD-1 monoclonal antibodyPhase 1Advanced Solid TumorsOncologyJan 2027
NCT06774963LNCB74Phase 1Ovarian CancerOncologyDec 2027
NCT06121700Anti-PD-1 monoclonal antibodyPhase 2AdenocarcinomaOncologyDec 2027
NCT06556199Anti-PD-1 monoclonal antibodyPhase 1Relapsed/Refractory Primary Central Nervous System LymphomaOncologyAug 2028
NCT07365592Anti-PD-1 monoclonal antibodyPhase 1Colorectal CancerOncologyDec 2029
NCT07460375LCB02APhase 1Advanced Solid TumorsOncologyFeb 2030

Targets

CLDN18 (1) TROP2 (1) PDCD1 (1)

Companies with the same targets

Akeso AstraZeneca Innovent Biologics (Suzhou) Astellas Sichuan Baili Pharmaceutical GSK Mabwell (Shanghai) Bioscience Bio-Thera Solutions Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.